Citation Tools

Download PDFPDF
Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes

Download to a citation manager

Cite this article as:
Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes